Compare Ascendis Pharma A/S (ASND) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Yum! Brands, Inc. — how do they compare? Ascendis Pharma A/S trades at $256 (market cap $16.67B), while Yum! Brands, Inc. trades at $149.2 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 2.4× Ascendis Pharma A/S's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | YUM | |
|---|---|---|
Market Cap | $16.67B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $168.16 |
52-Week Low | $189.74 | $138.21 |
Enterprise Value | $17.04B | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
YUM Brands trades at $148.91, up 2.46% with recent earnings beats offset by food safety concerns. Technical indicators show bearish momentum with support at $141, while fundamentals reveal strong revenue growth to $8.21B in 2025 and net income of $1.56B. The company recently completed the $1.2B sale of Pizza Hut China, streamlining operations amid cyclospora outbreak impacts on Taco Bell sales.
YUM presents a mixed outlook with 37% analyst buy ratings and $174.60 price target suggesting 17% upside, but faces near-term headwinds from food safety investigations and consumer sentiment. Long-term growth depends on KFC/Taco Bell execution and digital strategy success amid elevated debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
